Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Specimen Handling 456Magnetic Resonance Spectroscopy 347pembrolizumab 287Biopsy 245Carboplatin 228Cisplatin 194Cyclophosphamide 178Paclitaxel 160Nivolumab 153Gemcitabine 147Bevacizumab 126Radiotherapy 124Dexamethasone 110Pemetrexed 101fludarabine 96Fluorouracil 95atezolizumab 93Radiation 92Docetaxel 90venetoclax 89Doxorubicin 88durvalumab 85Oxaliplatin 85Rituximab 84Leucovorin 81Capecitabine 76Prednisone 73Lenalidomide 70X-Rays 69Etoposide 67

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ibritumomab tiuxetan × 30 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡